Q-omics provides the consensus-scored CATSPER1 profile across patient tissues and cancer cell-line models. CATSPER1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CATSPER1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CATSPER1 RNA expression shows 14,239 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight KIRC, and SARC as cancer lineages where CATSPER1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CATSPER1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CATSPER1 survival associations across molecular data types. CATSPER1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CATSPER1 RNA expression–survival associations across cancer types. High CATSPER1 expression shows unfavorable associations in KIRC, ACC, LGG, STAD, KIRP and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CATSPER1 RNA expression.
This table summarizes CATSPER1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CATSPER1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CATSPER1 shows lower tumor expression in LUSC and higher tumor expression in KIRC, THCA, HNSC, KIRP and COAD. The KIRC box plot shows higher CATSPER1 RNA expression in tumor versus normal tissue (log2 FC = +0.565, t-test p < 0.001).
This table shows molecular features associated with CATSPER1 in patient tissues and cancer cell lines. In patient samples, CATSPER1 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, CATSPER1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
